ClinicalTrials.gov
public full text
Public Domain
Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
This is a Phase I, open-label, uncontrolled, multicenter dose escalation and extension study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate safety / tolerability and preliminary effects of BEL-X-HG in patients with advanced refractory solid tumors. Dose escalation during the study will be made based on dose-limiting toxicity (DLT).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors#839548
- A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.#1150176
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors#847862
- BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit#855376
- A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer#1173261
Record · ID 863979
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive